Amelanotic melanoma (AM) of the heel is a very rare subtype of malignant melanoma in which the tumour cells, unlike other types of melanoma, are characterised by little or no melanin pigmentation. AM resembles many benign dermatological complications that often lead to late diagnosis of lesions, poor prognosis, and occasionally misdiagnosis at an early stage of the disease. We report a case of a 73-year-old man with a heel ulcer who was admitted to Al-Zahra Hospital (Isfahan, Iran). Chronic osteomyelitis was considered the primary diagnosis, and several courses of antibiotics were prescribed for the patient. The ulcer failed to improve after 9 months' of therapy, and because of an increase in the size of the ulcer and the growth of two tumours in the right heel, a biopsy of the lesion was conducted. The pathology report confirmed invasive AM. The present report emphasises the necessity to biopsy all skin lesions, even with low clinical significance, to avoid wrong subsequent treatments, prevent a delay in diagnosis, reduce misdiagnosis, and improve the survival rate of patients.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7949254PMC
http://dx.doi.org/10.1111/iwj.13338DOI Listing

Publication Analysis

Top Keywords

amelanotic melanoma
8
rare subtype
8
heel
4
heel amelanotic
4
melanoma
4
melanoma rare
4
subtype skin
4
skin cancer
4
cancer misdiagnosed
4
misdiagnosed foot
4

Similar Publications

Introduction: The aim of this study was to differentiate amelanotic choroidal lesions - amelanotic choroidal melanoma, choroidal metastasis, and choroidal granuloma using multimodal imaging.

Methods: Retrospective comparative chart review was done. Patients diagnosed with the abovementioned choroidal lesions from 2015 to 2022 were included.

View Article and Find Full Text PDF

Anorectal malignant melanoma (ARMM) is a rare and highly aggressive type of melanoma that originates in the anorectal area. It represents a small fraction of all melanoma cases and is often associated with poor prognosis due to its late presentation and challenging treatment options. Rectal malignant melanoma typically presents with symptoms such as rectal bleeding, pain, and obstructive symptoms.

View Article and Find Full Text PDF

Plantar acral melanoma: epidemiological, clinical, dermoscopic and histopathological features. A Brazilian cohort.

An Bras Dermatol

November 2024

Department of Internal Medicine, Faculty of Medicine, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil; Dermatology Unity, Hospital das Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.

Background: Acral melanomas (AM) are rare and approximately two-thirds of them occur on the soles of the feet beeing more prevalent in black and Asian individuals. Data on this subtype of melanoma are scarce in the Brazilian population.

Objectives: To describe and correlate the epidemiological, clinical, dermoscopic, and histopathological features of AM a.

View Article and Find Full Text PDF

Cyclin-Dependent Kinase Inhibitors in the Rare Subtypes of Melanoma Therapy.

Molecules

November 2024

Department of Histology and Embryology, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, 85-067 Bydgoszcz, Poland.

Melanoma occurs in various forms and body areas, not only in the cutis, but also in mucous membranes and the uvea. Rarer subtypes of that cancer differ in genomic aberrations, which cause their minor sensibility to regular cutaneous melanoma therapies. Therefore, it is essential to discover new strategies for treating rare forms of melanoma.

View Article and Find Full Text PDF

Amelanotic Melanoma-Biochemical and Molecular Induction Pathways.

Int J Mol Sci

October 2024

Department of Molecular and Cellular Biology, Wroclaw Medical University, Borowska 211A, 50-556 Wroclaw, Poland.

Article Synopsis
  • * Understanding the biochemical and molecular pathways involved in AM can help develop targeted therapies, though there are currently few specific biomarkers for this type of cancer.
  • * Current treatments focus on inhibiting certain genes (like BRAF and c-KIT) and combining therapies, such as BRAF with MAK inhibitors or immune checkpoint inhibitors, to improve patient outcomes.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!